Abstract
Tumor suppressor p53 is an attractive cancer therapeutic target because it can be functionally activated to eradicate tumors. Direct gene alterations in p53 or interaction between p53 and MDM2 proteins are two alternative mechanisms for the inactivation of p53 function. Designing small molecules to block the MDM2-p53 interaction and reactivate the p53 function is a promising therapeutic strategy for the treatment of cancers retaining wild-type p53. This review will highlight recent advances in the design and development of small-molecule inhibitors of the MDM2-p53 interaction as new cancer therapies. A number of these small-molecule inhibitors, such as analogs of MI-219 and Nutlin-3, have progressed to advanced preclinical development or early phase cinical trials.
References
102
Referenced
507
10.1038/sj.onc.1207116
10.1016/S0065-230X(08)60785-X
10.1038/35042675
10.1038/nrc864
10.1158/1078-0432.CCR-07-5136
10.1038/278261a0
10.1016/0092-8674(79)90293-9
10.1073/pnas.76.5.2420
10.1016/0092-8674(89)90045-7
10.1038/348747a0
10.1126/science.1978757
10.1016/j.critrevonc.2004.07.002
10.1016/0092-8674(92)90644-R
10.1002/j.1460-2075.1991.tb07676.x
10.1006/geno.1993.1058
10.1016/j.cell.2004.11.022
10.1038/358080a0
10.1038/sj.leu.2401619
10.2174/1568009053332636
10.1093/nar/26.15.3453
10.1038/modpathol.3880107
10.2174/1568009053332627
10.1038/sj.onc.1201702
10.1016/S0378-1119(99)00487-4
10.1093/emboj/19.19.5135
10.1016/0092-8674(93)90461-X
10.1016/S0002-9440(10)64853-5
10.1038/nature05541
10.1016/j.cell.2006.12.007
10.1038/nature05529
10.1038/nm0302-282
10.1038/nm1146
10.1016/j.molmed.2006.11.002
10.1126/science.1092472
10.1038/sj.cdd.4401921
10.1021/ja051147z
10.1073/pnas.0708917105
10.1007/s000180050273
10.1007/BF03402141
10.1101/gad.7.7a.1126
10.1038/378206a0
10.1038/378203a0
10.1128/MCB.23.2.462-473.2003
10.1128/MCB.13.7.4107
{'key': 'B43', 'first-page': '2523', 'volume': '9', 'author': 'Picksley SM', 'year': '1994', 'journal-title': 'Oncogene'}
/ Oncogene by Picksley SM (1994)10.1126/science.274.5289.948
10.4161/cc.3.4.801
10.1021/jm051122a
10.1158/1535-7163.MCT-08-0140
10.1021/jm049137g
10.1016/j.bmcl.2004.11.009
10.1158/1535-7163.MCT-05-0199
10.1002/anie.200462316
10.1158/1535-7163.MCT-04-0342
10.1021/jm060023+
10.1021/bi000930v
10.1021/jm034182u
10.1101/gad.8.10.1235
{'key': 'B56', 'first-page': '2141', 'volume': '13', 'author': 'Bottger V', 'year': '1996', 'journal-title': 'Oncogene'}
/ Oncogene by Bottger V (1996)10.1021/jm990966p
10.1021/ci00021a032
10.1021/ci000150t
10.1006/jmbi.1996.0897
10.1002/prot.10465
10.1023/A:1007996124545
10.1023/A:1016357811882
10.1021/ja073687x
10.1021/ja026861k
10.2174/0929867053363153
10.1016/j.bmcl.2006.04.009
10.1074/jbc.C600147200
10.1038/nature05194
10.1158/0008-5472.CAN-05-3832
10.4161/cc.7.13.6072
10.1074/jbc.M605405200
10.1074/jbc.M410233200
10.1158/1541-7786.MCR-07-0161
10.1158/1078-0432.CCR-08-0150
{'key': 'B74', 'first-page': '1169', 'volume': '54', 'author': 'el-Deiry WS', 'year': '1994', 'journal-title': 'Cancer Res.'}
/ Cancer Res. by el-Deiry WS (1994)10.1016/S1097-2765(00)80002-7
10.1073/pnas.0507493103
10.1016/j.ccr.2006.10.010
10.1182/blood-2005-02-0553
10.1161/01.RES.0000253975.76198.ff
10.1182/blood-2005-11-4465
10.1182/blood-2005-12-5148
10.1182/blood-2005-08-3273
10.1182/blood-2007-09-112698
10.1182/blood-2005-04-1489
10.1016/j.bcmd.2007.04.002
10.1158/0008-5472.CAN-04-3576
10.1158/0008-5472.CAN-06-1527
10.1038/sj.onc.1202281
10.1002/j.1460-2075.1996.tb00919.x
10.1128/MCB.20.3.1001-1007.2000
10.1016/S0014-5793(99)00254-9
10.1038/ng714
10.1128/MCB.22.15.5527-5538.2002
10.4161/cc.6.19.4740
10.1172/JCI30945
10.1038/362847a0
10.1002/stem.150082
Dates
Type | When |
---|---|
Created | 16 years, 10 months ago (Oct. 3, 2008, 5:19 p.m.) |
Deposited | 3 years, 10 months ago (Oct. 16, 2021, 4:50 a.m.) |
Indexed | 4 weeks, 1 day ago (July 22, 2025, 7:03 a.m.) |
Issued | 16 years, 6 months ago (Feb. 1, 2009) |
Published | 16 years, 6 months ago (Feb. 1, 2009) |
Published Print | 16 years, 6 months ago (Feb. 1, 2009) |
@article{Shangary_2009, title={Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy}, volume={49}, ISSN={1545-4304}, url={http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094723}, DOI={10.1146/annurev.pharmtox.48.113006.094723}, number={1}, journal={Annual Review of Pharmacology and Toxicology}, publisher={Annual Reviews}, author={Shangary, Sanjeev and Wang, Shaomeng}, year={2009}, month=feb, pages={223–241} }